Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report

BACKGROUND: HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases and are predominantly observed in non-smokers, females, and adenocarcinoma patients. Although afatinib is recommended for treating NSCLC patients with HER2 mutation, the therapy is most efficaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yan, Zheng, Aihong, Zhu, Xiuming, Song, Jia, Xue, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287414/
https://www.ncbi.nlm.nih.gov/pubmed/30584328
http://dx.doi.org/10.2147/OTT.S182812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287414/
https://www.ncbi.nlm.nih.gov/pubmed/30584328
http://dx.doi.org/10.2147/OTT.S182812

Ejemplares similares